Fri, Nov 28, 2014, 11:16 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

Facebook, Inc. (FB) Message Board

scanit2008 95 posts  |  Last Activity: 2 hours 31 minutes ago Member since: Feb 4, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Twitter: @AmarantusBio .... 8,631 followers

    by smittysghost Nov 24, 2013 1:21 PM
    scanit2008 scanit2008 Nov 29, 2013 8:52 AM Flag

    Retweet the company's tweets.

  • Which crisis spikes gold to $1,500?

  • scanit2008 by scanit2008 Nov 29, 2013 8:59 AM Flag

    Buying op.

  • Reply to

    @AmarantusBio .... 8,606 followers

    by smittysamigo Nov 21, 2013 10:26 AM
    scanit2008 scanit2008 Nov 29, 2013 9:00 AM Flag

    Best buy in the market for under a nickle.

  • Reply to

    AMBS = MANF + Diabetes + Novartis

    by aunttizzy Nov 22, 2013 10:43 AM
    scanit2008 scanit2008 Nov 29, 2013 9:02 AM Flag

    Best opportunity in the market for substantial returns over the next twelve months.

  • Reply to

    AMBS

    by wcoastguy2008 Nov 21, 2013 1:03 PM
    scanit2008 scanit2008 Dec 2, 2013 12:57 PM Flag

    Starting to move.

    Due diligence.

  • Zack's analyst, Jason Napadano, says it's a buy with 500% upside.

    Due diligence.

    Follow the company on Twitter: @AmarantusBio .... 8,639 followers

    p.s. Currently under a nickle.

  • scanit2008 scanit2008 Dec 2, 2013 1:19 PM Flag

    AMBS will be above .10 by the end of the month.

    Twitter: @AmarantusBio .... 8,639 followers

  • scanit2008 scanit2008 Dec 3, 2013 9:21 AM Flag

    Ask him about MANF as it relates to the field of diabetes and the Novartis rumors.

  • scanit2008 by scanit2008 Dec 3, 2013 9:23 AM Flag

    Won't be under a nickle much longer.

  • scanit2008 by scanit2008 Dec 3, 2013 9:38 AM Flag

    SAN FRANCISCO and MIAMI, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has entered into an exclusive option agreement with the University of Miami to license the Bascom Palmer Eye Institute's method of use intellectual property surrounding the use of MANF and CDNF for the treatment of retinal diseases. The option agreement includes all intellectual property covering the use of the MANF-Family of proteins (MANF and CDNF) for retinal diseases including age-related macular degeneration, glaucoma, inherited retinal disorders (including Retinitis Pigmentosa), sporadic retinal disorders, other degenerative retinal disorders, and retinal injuries. This option agreement follows previously announced positive data for MANF in the S334ter Type 3 genetic mouse model of Retinitis Pigmentosa. The Company owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications.

    "The potential for MANF to treat diseases and injuries of the retina represents a tremendous commercial opportunity resulting from the strategic shift initiated last year to identify drugable orphan indications," said Gerald E. Commissiong, President & CEO of Amarantus. "As we look to complete the reprioritization of the MANF pipeline towards orphan diseases, this agreement marks a critical milestone that enables the Company to gain worldwide control of the patent prosecution process for both MANF and CDNF in this key set of indications. We believe we are now in the unique position to have control over the commercial development over both MANF and CDNF in retinal indications and are absolutely thrilled to have positioned the Company in this manner from an intellectual property

  • Reply to

    AMBS News

    by scanit2008 Dec 3, 2013 9:38 AM
    scanit2008 scanit2008 Dec 3, 2013 9:39 AM Flag

    Next orphan indication will be for MANF in the field of diabetes.

  • Reply to

    "AMBS" - 300% Upside In Three Months

    by scanit2008 Nov 8, 2013 9:22 AM
    scanit2008 scanit2008 Dec 3, 2013 9:40 AM Flag

    SAN FRANCISCO and MIAMI, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has entered into an exclusive option agreement with the University of Miami to license the Bascom Palmer Eye Institute's method of use intellectual property surrounding the use of MANF and CDNF for the treatment of retinal diseases. The option agreement includes all intellectual property covering the use of the MANF-Family of proteins (MANF and CDNF) for retinal diseases including age-related macular degeneration, glaucoma, inherited retinal disorders (including Retinitis Pigmentosa), sporadic retinal disorders, other degenerative retinal disorders, and retinal injuries. This option agreement follows previously announced positive data for MANF in the S334ter Type 3 genetic mouse model of Retinitis Pigmentosa. The Company owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications.

    "The potential for MANF to treat diseases and injuries of the retina represents a tremendous commercial opportunity resulting from the strategic shift initiated last year to identify drugable orphan indications," said Gerald E. Commissiong, President & CEO of Amarantus. "As we look to complete the reprioritization of the MANF pipeline towards orphan diseases, this agreement marks a critical milestone that enables the Company to gain worldwide control of the patent prosecution process for both MANF and CDNF in this key set of indications. We believe we are now in the unique position to have control over the commercial development over both MANF and CDNF in retinal indications and are absolutely thrilled to have positioned the Company in this manner from an intellectual property standpoint in the neurotrophic factor space."

    "The data generated in this set of key experiments using a highly relevant genetic mouse model of Retinitis Pigmentosa reproducibly demonstrates the neuroprotective activity of intravitreal MANF injection in protecting cellular degeneration, a key unmet need in this orphan indication," said David A. Lowe, PhD, newly appointed Board member of Amarantus whose advisory firm NeuroAssets is now developing MANF on behalf of the Company. "As we complete the clinical development plans and identify the best dosing regimen for MANF intervention to demonstrate a robust result in a well-controlled clinical trial setting in Retinitis Pigmentosa, we are pleased that we will be working with the leading ophthalmology unit in the country, with access to well characterized patients and a deep understanding of the progression of this terrible progressive degenerative retinal disorder."

    The Bascom Palmer Eye Institute at the University of Miami has been ranked No. 1 nationally in ophthalmology in U.S. News & World Report's annual "Best Hospitals" rankings for 10 consecutive years. Founded in 1962, Bascom Palmer is the largest ophthalmic care, research and educational facility in the southeastern United States. Its staff treats more than 250,000 patients and performs more than 13,000 surgeries annually. At the forefront of innovation in ophthalmology for more than five decades, the institute's physicians and scientists are internationally recognized for their expertise in every eye disorder, including glaucoma, macular degeneration, diabetic retinopathy, cataracts, dry eye, eye cancers and eye diseases in children.

  • Opens the door for the up listing. :-)

  • 60% short volume yesterday and 46% today. They are digging the hole deeper everyday.

  • Reply to

    Thank you mfm401k

    by j_bif Dec 4, 2013 11:48 PM
    scanit2008 scanit2008 Dec 5, 2013 5:55 AM Flag

    regsho.finra(dot)org/FORFshvol20131204.txt

    Replace the (dot) with a .

    Change the date in the link to get the daily numbers after 6:30 p.m. eastern time.

  • AMEN!!!

  • scanit2008 by scanit2008 Dec 5, 2013 9:17 AM Flag

    Solantey On Ihub:

    This is setting up for a "short squeeze" run back to the 52 week high in the .20 range. I think it will hold that range and move higher from there as the time frame for the up listing to NASDAQ shrinks. My expectation is that the up listing will occur in the second quarter of 2014.

    The shorts are struggling to keep a lid on the share price as follows:

    12/2: 2,582,665 Shares Traded - Short Shares: 792,534 30.6%

    12/3: 4,894,225 Shares Traded - Short Shares: 2,858,364 58.4%

    12/4: 6,053,177 Shares Traded - Short Shares - 2,686,009 44.4%

    6,336,907 Short Shares Over the last three sessions.

  • Reply to

    Short Squeeze

    by scanit2008 Dec 5, 2013 9:17 AM
    scanit2008 scanit2008 Dec 5, 2013 9:52 AM Flag

    regsho.finra(dot)org/FORFshvol20131204.txt

    Replace the (dot) with a .

    Change the date in the link to get the daily numbers after 6:30 p.m. eastern time.

  • scanit2008 by scanit2008 Dec 5, 2013 9:58 AM Flag

    Second quarter 2014 sounds about right.

FB
77.70+0.08(+0.10%)Nov 28 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.